Kornimate/medical-research-clean huggingface dataset:
2-cohort study of adult patients with severe hemophilia a in greece

Conditions: Hemophilia A

Summary: this study is a prospective, single center, observational, 2-cohort study of adult patients with severe hemophilia a. there is no randomization procedure and all patients will be treated as per usual clinical practice. patients will be followed up for 18 months after enrolment.

the primary therapy for hemophilia is coagulation factor replacement, given either episodically on demand (od) for the treatment of acute bleeds or prophylactically to prevent them. the last years there has been an interest to study the comparative effectiveness of od vs. sp (secondary prophylaxis) treatment strategies so as to create an evidence based platform to guide both clinical decision making and quantify the economic aspects of each treatment alternative. in greece relevant information is lacking, thus it is imperative to study how patients on different treatment strategies are managed in a real-life setting in greece, including the main factors associated with increased health care utilization, clinical success and patient well being.

Eligibility criteria:
inclusion criteria: * patients diagnosed with severe hemophilia a. * age ≥18 years old * patients able to read and write * patients receiving factor viii substitute therapy, either on-demand or as secondary prophylaxis. * patients under the same therapeutic strategy (on demand or secondary prophylaxis) for at least 6 months prior to enrolment. exclusion criteria: * patients that have developed inhibitors against factor viii. * patients participating in an investigational program with interventions outside of routine clinical practice.

Keywords: cost clinical outcomes quality of life on demand treatment secondary prophylaxis
daily versus alternate day iron supplementation for the treatment of iron deficiency anemia in pregnancy

Conditions: Pregnancy Related; Iron Deficiency Anemia of Pregnancy

Summary: the target population for our study is pregnant women in the first or second trimester with a diagnosis of iron deficiency anemia. if a subject is eligible, written consent will be obtained by person to person contact. eligible participants will be randomized to receive either daily oral iron supplementation or every other day oral iron supplementation.

eligible pregnant women in the first or second trimester who carry a diagnosis of iron deficiency anemia as defined by the american college of obstetrics and gynecology will be approached, consented, and randomized to receive either daily oral ferrous sulfate (325mg) supplementation or every other day oral ferrous sulfate (650mg). participants will undergo a phone survey 2-4 weeks after starting the study to assess for side effects. participants will continue routine care and surveillance of iron deficiency in pregnancy until the end of pregnancy.

Eligibility criteria:
inclusion criteria: * hemoglobin less than 11 g/dl in the first trimester or less than 10.5 g/dl in the second trimester * microcytic anemia * singleton gestation in the first or second trimester exclusion criteria: * malabsorptive disorder or history of restrictive or malabsorptive gastric surgery * known diagnosis of anemia other than iron deficiency (thalassemia, macrocytic, sickle cell, etc.) * history of cardiopulmonary disease * severe anemia requiring parental infusion or transfusion of blood products

Keywords: pregnancy iron deficiency anemia iron supplementation
a pilot study of a new miralax® dose formulation for use in constipated children

Conditions: Constipation

Summary: to evaluate patient acceptance of a new miralax dose formulation in children currently treated with polyethylene glycol 3350 powder for treatment of constipation.

to evaluate patient acceptance of a new miralax dose formulation in children currently treated with polyethylene glycol 3350 powder for treatment of constipation.

Eligibility criteria:
inclusion criteria: 1. male or female constipated outpatients between the ages of 4 and 16 2. currently taking a dose of less than or equal to 17g of peg 3350 powder that has been consistent for at least 4 weeks 3. current treatment is considered successful - defined as greater than 2 bowel movements per week with no accidents 4. are otherwise in good health, as judged by a physical examination 5. if female and of childbearing potential, patient must be using oral contraceptives, depot contraceptives, intrauterine device, or testifies that she is monogamous with a vasectomized partner, or practices abstinence and will continue to do so during the duration of study 6. in the investigator's judgment, patient or guardian is mentally competent to sign an instrument of informed consent exclusion criteria: 1. patients with heme positive stool at baseline exam 2. patients who are impacted at baseline exam 3. patients that are not receiving peg 3350 4. patients on peg 3350 that continue to have problems 5. patients with known or suspected perforation or obstruction 6. patients with a history of gastric retention, inflammatory bowel disease, bowel resection, or colostomy 7. patients with a known history of organic cause for their constipation. 8. patients currently using medications known to cause constipation. these include opiates, antidepressants, ssri's, antimotility agents and anticholinergics. 9. patients who are breastfeeding, pregnant, or intend to become pregnant during the study 10. female patients of childbearing potential who refuse a pregnancy test 11. patients who, in the opinion of the investigator, should not be included in the study for any reason, including inability to follow study procedure 12. patients with known allergy to peg or peg containing medications 13. patients who, within the past 30 days have participated in an investigational clinical study

Keywords: constipation pediatric
satraplatin and paclitaxel in patients with advanced non-small cell lung cancer

Conditions: Non-small Cell Lung Cancer

Summary: the purpose of this trial is to study the combination regimen of satraplatin and paclitaxel in the first-line treatment of patients with advanced non-small cell lung cancer (nsclc).

this trial is designed to study the efficacy and safety of a novel oral platinum analog, satraplatin, in combination with another chemotherapy drug, paclitaxel, for the first line of treatment (patients who have not received chemotherapy for disease that has metastasized) of patients with advanced nsclc. what is satraplatin: satraplatin is a member of the platinum-based class of chemotherapy drugs. platinum-based drugs have been clinically proven to be one of the most effective classes of anticancer therapies. unlike the currently marketed platinum-based drugs, satraplatin can be given orally.

Eligibility criteria:
inclusion criteria: * histologically confirmed advanced nsclc * patients must not have received any prior antineoplastic chemotherapy or investigational product for lung cancer prior to study entry. * patients must have at least one unidimensionally measurable lesion definable by magnetic resonance imaging (mri) or computed tomography (ct) scan. * ecog performance status of ≤ 2.

Keywords: advanced non-small cell lung cancer (nsclc)
stearoyl-coa desaturase and energy metabolism in humans

Conditions: Healthy; Obesity

Summary: the aim of this study is to examine if changing stearoyl-coenzyme a desaturase-1 (scd1) activity through dietary interventions can increase energy metabolism in humans.

in rodents as well as humans, high stearoyl-coenzyme a desaturase-1 (scd1) activity is considered to be involved in development of obesity. in animal models, polyunsaturated fatty acids (pufa) inhibit scd1 gene expression and at the population level, dietary pufa and plasma pufa show strong inverse associations with plasma scd indices. emerging evidence also suggests a role for the sulphur amino acid cysteine in regulating scd1 activity and obesity. the overall aim of the project is to examine if interventions that lowers scd1 activity lead to increased energy metabolism. in this project, the investigators will conduct dietary intervention trials to evaluate the effects of short-term consumption of a diet rich in polyunsaturated fatty acids (pufa) and low in cysteine and its precursor methionine (pufa-cys/met) vs. a diet rich in saturated fatty acids (sfa) and cysteine/methionine (sfa+cys/met) on scd1 activity, lipids, amino acids, glucose and other biomarkers related to energy metabolism, in healthy normal-weight subjects. healthy volunteers will be randomized to the pufa-cys/met or sfa+cys/met diets receiving supplements/meals in a single dose or for 7 days. this study is a pilot study, with main focus on feasibility, tolerance and side effects. if the pilot shows positive results in terms of side effects, safety and tolerance, the investigators will follow-up by including obese subjects in a longer dietary intervention.

Eligibility criteria:
inclusion criteria: * healthy normal-weight (bmi 20-25 kg/m2) exclusion criteria * high physical activity * smoking * high intake of fatty fish or cod liver oil * drugs * pregnancy or breastfeeding * chronic disease

Keywords: energy metabolism
covid-19 pandemic on health care and rehabilitation outcomes

Conditions: Hip Fractures; Covid19

Summary: fragility fracture is easily associated with a clinical worsening of patients in terms of quality of life and disability in the medium and long term. following this traumatic event, more than half of the patients are unable to recover pre-fracture motor skills such as the ability to walk. the impact of the covid-19 pandemic on this type of patient has not been described and it is easy to hypothesize that, given their intrinsic frailty condition, they may have been significantly affected by changes in care pathways.

the global health emergency due to the spread of covid-19 has caused unprecedented pressure on the health systems of the various countries involved. covid-19 has had a direct impact on the health status of people with an extremely high number of icu admissions and deaths, but it has also led to a series of equally strong indirect consequences as described in various fields by multiple authors. in order to cope with the great health demand linked to the epidemic, hospitals had to invest human and physical resources, subtracting them from other care activities: operating theaters, surgical and non-surgical departments and the related staff normally destined for patient care were redirected and relocated to the care of covid patients. in the field of orthopedic surgery in the first phase of the spread of the epidemic, all non-essential interventions have been postponed and for essential interventions specific paths have been created at hospitals capable of operating even during the pandemic. this organization has led to a reduction in the overall number of hospitalized patients but the number of old patients operated for hip fracture has not decreased. from the point of view of the impact of the covid-19 pandemic on all patients operated for hip fracture with respect to the care outcomes during the postoperative hospital stay, the available data are lacking.

Eligibility criteria:
inclusion criteria: * patients diagnosed with fragility hip fracture such as pertrochanteric fracture, femoral neck fracture and subtrochanteric fracture * age 65 or older exclusion criteria: * patients diagnosed with a fragility hip fracture whose nursing record was not scanned at the time of the investigation * patients with fragility fractures of the diaphyseal and / or distal femur and acetabular fractures.
exercise as medicine for people with cancer sweden

Conditions: Prostate Cancer; Breast Cancer; Colorectal Cancer

Summary: regular exercise has been shown to have beneficial health effects in cancer survivors, including improving quality of life and other important health outcomes. however, providing people with cancer with easily accessible, high-quality exercise support and programs is a challenge. therefore, there is a need to develop easily accessible exercise programs that draw upon the current evidence. supervised, distance-based exercise programs have the benefit of reaching out to many people while providing the support of an exercise professional. the aim of the ex-med cancer sweden trial is to examine the effectiveness of a supervised, distance-based exercise program, in people previously treated for breast, prostate, or colorectal cancer, on health-related quality of life (hrqol), as well as other physiological and patient-reported health outcomes. participants will be randomized to a 3-month supervised, distance-based exercise program or to a usual care control group. testing timepoints are baseline, 3 months (end of intervention) and 6 months (3 month followup). at these timepoints, patients will be asked to fill in online questionaires, and and undergo physical tests. a selection of the particpants and personal trainers involved in the intervention will also be invited to participate in focus group discussion or interviews about the experiences of being involved in the ex-med cancer sweden program.

the primary aim of the study is to examine the effectiveness of ex-med cancer sweden on health-related quality of life in people diagnosed with breast, prostate, and colorectal cancer. the secondary aims are to examine the effect of the program on other important endpoints such as physical activity level, physical function, muscle strength, exercise capacity, symptoms, and body composition (lean and fat mass). to determine the sustainability of the effects of the supervised program, the study includes a 3-month follow-up time point (6 months post-baseline)

Eligibility criteria:
inclusion criteria: * 18 years or older * males or females * people diagnosed with any type of stage i-iiia breast, prostate or colorectal cancer who have undergone and completed curative treatment (note: participants are eligible if they are currently receiving/scheduled to receive anti-hormonal therapy) at the karolinska comprehensive cancer centre, sweden exclusion criteria: * currently receiving or scheduled to receive cancer treatment (except anti-hormonal therapy) * any medical conditions that may prevent safe participation in the testing or exercise demands of the study * performing regular exercise throughout the last month defined as undertaking at least 150 mins moderate intensity aerobic exercise and two or more structured resistance exercise sessions per week * unable to read and speak swedish.

Keywords: exercise cancer fitness distance-based home-based
folfirinox + cetuximab chemotherapy, in first line, with wild ras and according to braf status in metastatic colorectal cancer

Conditions: Colorectal Cancer

Summary: this retrospective study, will evaluate patient outcomes after triplet chemotherapy (folfirinox) (5 fluorouracil + oxaliplatin + irinotecan) plus cetuximab 1st line treatment focusing on efficacy and safety in a ras (kras, nras (neuroblastoma rat sarcoma viral oncogene homolog) wild-type metastatic colorectal cancer population, and according to braf (murine sarcoma viral oncogene homolog b) status and primary tumor location.

in europe, there are 447,000 new cases of colorectal cancer each year. approximately 25% of patients present with metastases at initial diagnosis and almost 50% of patients with mcrc (metastatic colorectal cancer) will develop metastases . chemotherapy represents the backbone of treatment, and survival is linked with the administration of all three active cytotoxic agents (5-fluorouracil/folinate, oxaliplatin, and irinotecan) in the first line treatment of metastatic colorectal disease. monoclonal antibodies such as cetuximab in combination with chemotherapy are a first line treatment option in metastatic ras (rat sarcoma viral oncogene homolog) wild type metastatic colorectal cancer (mcrc). phase ii trials evaluating triplet chemotherapy plus cetuximab reported interesting results in terms of efficacy (response rate, resectability...), but at the price of an increased rate of toxic effects. this retrospective study, will evaluate patient outcomes after triplet chemotherapy (folfirinox) (5 fluorouracil + oxaliplatin + irinotecan) plus cetuximab 1st line treatment focusing on efficacy and safety in a ras (kras, nras (neuroblastoma rat sarcoma viral oncogene homolog) wild-type mcrc (metastatic colorectal cancer) population, and according to braf (murine sarcoma viral oncogene homolog b) status and primary tumor location.

Eligibility criteria:
inclusion criteria: 1. colorectal cancer confirmed as ras wild by tumor tissue analysis 2. non resectable and measurable metastatic disease 3. patients treated with folfirinox + cetuximab in first line metastatic disease 4. males or females aged over 18 years. exclusion criteria: 1. known brain metastases 2. ras not assessable (e.g., material not available or insufficient) 3. the first administration of cetuximab was more than 30 days after the first administration of folfirinox 4. history of other malignancy in the last 5 years. patients with prior history of in situ cancer or basal or squamous cell skin cancer are eligible. patients with other malignancies are eligible if they were cured by surgery alone or surgery plus radiotherapy and have been continuously disease-free for at least 5 years

Keywords: colorectal cancer first line folfirinox + cetuximab
co-design and pilot study in vr-based physical activity and cognitive training

Conditions: Dementia; Physical Activity; Reminiscence Therapy; Co-design; Digital Health Intervention; Alzheimer&#39;s Disease

Summary: physical activity and reminiscence therapy alone have been studied with no clear effectiveness in alzheimer's disease, but their combined intervention remains unknown. the health sector is now advocating the use of multiple interventions in dementia care. here, we aim to develop a physical activity and reminiscence therapy device and investigate its effectiveness in older adults with dementia. as there is no existing device for the oldest old, who typically have frailty and comorbidities, we need to first design and co-design a novel device and conduct pilot studies for its feasibility, perception, sustained adoption (adherence) and then preliminary efficacy (usually pilot or phase i, and often single arm).

to slow the progression of alzheimer's disease (ad), we need essentially design and co-design the interventional device to be effective for intervention. and since the oldest group is at high risk of dementia and ad, we wanted to address the needs of this forgotten group. there is no existing device or equipment designed for their intervention. in addition, their ability to sustain physical activity is relatively short, around 5-10 minutes, far less than the duration of normal physical activity. hence, we need to ensure that the device is well accepted and likely to be used by the target group. then we need to test its effectiveness.

Eligibility criteria:
inclusion criteria: * people who aged above 60 * people who can pedal the usual rehabilitation bike * people who are willing to attend this study exclusion criteria: * people who cannot cycle usual rehabilitation bike (assessed by care professionals) * people who cannot finish moca,
prevalence,knowledge and attitude of hiv /aids in luxor

Conditions: HIV/AIDS

Summary: human immunodeficiency virus infection is a global pandemic problem. about 35.3 million infected people in the world, so causing a great social, economical, political and cultural problems worldwide. in 1986 egypt's first aids case was discovered , since then the number of infected cases cases are increasing.according to united nations 2016 statistics, there are about 11,000 infected people living with human immunodeficiency virus in egypt.

human immunodeficiency virus is a lentivirus that causes the infection and over time leading to acquired immunodeficiency syndrome. the virus spread primarily by unprotected sex including vaginal, anal and oral sex, contaminated blood transfusions, infected needles, and from mother to child during pregnancy, delivery, or from milk during breastfeeding. in 1986 egypt's first aids case was discovered , since then the number of infected cases cases are increasing.according to united nations 2016 statistics, there are about 11,000 infected people living with human immunodeficiency virus in egypt. according to the national aids program, the primary mode of transmission is heterosexual intercourse, followed by homosexual intercourse , renal dialysis , and blood transfusion others include street children, prisoners, and refugees, female sex workers, men have sex with men, and injecting drug users. human immunodeficiency virus related stigma and discrimination is a great barrier to effectively fighting the disease epidemic. this study will assess prevalence, knowledge, attitudes of human immunodeficiency virus and acquired immunodeficiency syndrome people in luxor governorate in upper egypt.

Eligibility criteria:
inclusion criteria: 1-people living in luxor. 2 subjects of high risk groups as men have sex with men, children street, female sex workers. 3-people clinically diagnosed as hiv/aids. 4-people in contact with hiv/aids patients. exclusion criteria: 1 - subjects outside luxor 2- people refused to consent 3- mentally disordered patients
a study to learn about the study medicines called enzalutamide and abiraterone in people with metastatic castration-resistant prostate cancer

Conditions: Prostatic Neoplasms, Castration-Resistant

Summary: the purpose of this real-world study is to learn about the effects of 2 study medicines called enzalutamide and abiraterone used to treat metastatic castration-resistant prostate cancer (mcrpc). prostate cancer is one of the most common cancers in men. the prostate is a gland in the male body that helps make semen. most prostate cancers need male sex hormones, such as testosterone, to grow. prostate cancer that keeps growing even when the amount of testosterone in the body is reduced to very low levels is known as "castration-resistant". metastatic cancer is a cancer that has spread to other parts of the body. this is a real-world study, not a clinical trial. this means that researchers will look at what happens when men receive the treatments prescribed by their own doctor as part of their usual healthcare treatment. in this study, researchers will use information from the flatiron electronic health record (ehr) database. the study will include patients' information from the database for men who: * were confirmed by medical tests to have mcrpc * started first-line treatment with enzalutamide or abiraterone (index date) for mcrpc * had not received chemotherapy treatment before index date * were 18 years of age or older on index date men who are part of this study will receive enzalutamide or abiraterone as part of their usual treatment for mcrpc. we will compare the following between men receiving enzalutamide and men receiving abiraterone: * time from treatment start until death, * treatment duration, and * time to next treatment. this study will use patient information from the database until the end of information that is available.


Eligibility criteria:
inclusion criteria: * male with metastatic prostate cancer diagnosis and abstracted castration-resistant prostate cancer diagnosis * initiated enzalutamide or abiraterone within 14 days prior to or after the metastatic castration-resistant prostate cancer diagnosis. the initiation date of enzalutamide or abiraterone will be defined as the index date. * at least 18 years old at the index date exclusion criteria: * received chemotherapy, novel hormonal therapy, radium-223, olaparib/rucaparib, or immunotherapy prior to the index date * had a prior history of other cancers

Keywords: metastatic castration-resistant prostate cancer mcrpc enzalutamide abiraterone overall survival os treatment duration